2. Academic Validation
  3. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells

  • Biochem Pharmacol. 2014 Mar 1;88(1):36-45. doi: 10.1016/j.bcp.2013.12.019.
Stephen M F Jamieson 1,  Yongchuan Gu 2,  Donya Moradi Manesh 3,  Jad El-Hoss 3,  Duohui Jing 3,  Karen L Mackenzie 3,  Christopher P Guise 1,  Annika Foehrenbacher 2,  Susan M Pullen 2,  Juliana Benito 4,  Jeffrey B Smaill 1,  Adam V Patterson 1,  Medhanie A Mulaw 5,  Marina Konopleva 4,  Stefan K Bohlander 6,  Richard B Lock 3,  William R Wilson 7
Affiliations

Affiliations

  • 1 Auckland Cancer Society Research Centre, the University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand.
  • 2 Auckland Cancer Society Research Centre, the University of Auckland, Auckland, New Zealand.
  • 3 Children's Cancer Institute Australia for Medical Research, University of New South Wales, Sydney, Australia.
  • 4 Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • 5 Comprehensive Cancer Centre Ulm, Institute for Experimental Tumor Research, University of Ulm, Germany.
  • 6 Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand.
  • 7 Auckland Cancer Society Research Centre, the University of Auckland, Auckland, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, the University of Auckland, Auckland, New Zealand. Electronic address: [email protected].
PMID: 24434189 DOI: 10.1016/j.bcp.2013.12.019
Abstract

Aldo-keto reductase 1C3 (AKR1C3, EC 1.1.1.188) metabolises steroid Hormones, prostaglandins and xenobiotics, and activates the dinitrobenzamide mustard prodrug PR-104A by reducing it to hydroxylamine PR-104H. Here, we describe a functional assay for AKR1C3 in cells using the fluorogenic probe coumberone (a substrate for all AKR1C isoforms) in conjunction with a specific inhibitor of AKR1C3, the morpholylurea SN34037. We use this assay to evaluate AKR1C3 activity and PR-104A sensitivity in human leukaemia cells. SN34037-sensitive reduction of coumberone to fluorescent coumberol correlated with AKR1C3 protein expression by immunoblotting in a panel of seven diverse human leukaemia cell lines, and with SN34037-sensitive reduction of PR-104A to PR-104H. SN34037 inhibited aerobic cytotoxicity of PR-104A in high-AKR1C3 TF1 erythroleukaemia cells, but not in low-AKR1C3 Nalm6 pre-B cell acute lymphocytic leukaemia (B-ALL) cells, although variation in PR-104H sensitivity confounded the relationship between AKR1C3 activity and PR-104A sensitivity across the cell line panel. AKR1C3 mRNA expression showed wide variation between leukaemia patients, with consistently higher levels in T-ALL than B-ALL. In short term cultures from patient-derived paediatric ALL xenografts, PR-104A was more potent in T-ALL than B-ALL lines, and PR-104A cytotoxicity was significantly inhibited by SN34037 in T-ALL but not B-ALL. Overall, the results demonstrate that SN34037-sensitive coumberone reduction provides a rapid and specific assay for AKR1C3 activity in cells, with potential utility for identifying PR-104A-responsive leukaemias. However, variations in PR-104H sensitivity indicate the need for additional biomarkers for patient stratification.

Keywords

Aldo-keto reductase 1C3; Fluorogenic assays; Leukaemia; PR-104; SN34037.

Figures
Products